Contact the editorial team

What we respond to

We read every editorial message that arrives through this form. We respond to: factual corrections to the dossier (with a citation to a primary source that supports the correction); suggestions of peer-reviewed papers, ClinicalTrials.gov entries, FDA briefings, or anti-doping standards that should be added to the references; questions about editorial scope; and questions about the entity that publishes the dossier.

We do not respond to: requests to purchase CJC-1295; requests for vendor recommendations; requests for dosing guidance, treatment recommendations, or any other medical advice; vendor outreach asking to be linked, listed, mentioned, or advertised on the site; affiliate program proposals; or partnership offers from telehealth, compounding, or wellness operators.

Editorial contact form

A simple form follows below. Required fields are name, email, message category, and message. Submissions arrive at our editorial inbox and are reviewed within seven days. We do not subscribe submitters to any mailing list, and we do not share submitted information with third parties.

If you prefer plain email, the editorial address is published in the form's accessible label and in the footer of every page.

Disclaimer

This contact form is not a medical-advice service. We are not clinicians. We do not provide individual guidance on the use of CJC-1295 or any other compound. We do not sell CJC-1295. We do not refer readers to vendors. Readers seeking medical guidance should consult a licensed healthcare professional. Readers seeking to acquire any peptide or pharmaceutical should pursue that through channels appropriate to their jurisdiction and circumstance; this site is not such a channel.